About our focus—Aytu is different
Aytu is not a traditional research company. By acquiring or licensing approved, commercialized products and late-stage development therapeutics, we bring novel and needed treatments to market and to the millions of patients that need them. Novel products that can really help people feel better—and these products can make an impact today on patients’ health and well-being.
We are focused on commercializing novel products that address significant patient needs
Aytu is dedicated to better health and better living for the patients we serve.
Aytu products at a glance
CEFACLOR (cefaclor oral suspension) is a second-generation cephalosporin antibiotic suspension and is indicated for the treatment of numerous common infections caused by Streptococcus pneumoniae, Haemophilus influenzae, staphylococci, and Streptococcus pyogenes, and others.
KARBINAL™ ER (carbinoxamine maleate extended-release oral suspension) is an H 1 receptor antagonist (antihistamine) indicated to treat various allergic conditions including seasonal and perennial allergic rhinitis, vasomotor rhinitis, and other common allergic conditions.
NATESTO® (testosterone) nasal gel, the only FDA-approved nasally administered testosterone indicated for replacement therapy in adult males with a deficiency or absence of endogenous testosterone due to primary hypogonadism.
POLY-VI-FLOR® and TRI-VI-FLOR® are two complementary prescription fluoride-based supplement product lines containing combinations of vitamins and fluoride in various oral formulations. These prescription supplements are prescribed for infants and children to treat or prevent fluoride deficiency due to poor diet or low levels of fluoride in drinking water and other sources.
TUZISTRA® XR (Codeine Polistirex and Chlorpheniramine Polistirex) is the only codeine-based extended-release oral suspension cough-cold treatment in the US prescription cough-cold market.
ZOLPIMIST® (zolpidem tartrate) Oral Spray, the only FDA-approved oral spray zolpidem product indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation.
THE MiOXSYS® SYSTEM A novel, rapid in vitro diagnostic semen analysis system with the potential to become a standard of care in the diagnosis and management of male infertility.